5-Jan-2026 8:15 AM CST - Business Wire Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. During the presentation, the Company will unveil its new five-year strategy, which will guide the Companys next phase of gro
4-Nov-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentations at Upcoming November Investor Conferences Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, at 11:30 AM GMT (6:30 AM ET) in London A live audio webcast of each presentation will b
30-Oct-2025 7:00 AM CST - Business Wire Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed recent business highlights. Alnylams impressive third quarter financial results underscore our ability to consistently deliver innovative medicines to patients around the world, said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. While only in our se
16-Oct-2025 7:00 AM CST - Business Wire Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2025 results as well as expectations for the future via conference call on Thursday, October 30, 2025 at 8:30 am ET. A live audio w
31-Aug-2025 2:38 PM CST - Business Wire Alnylam wird Zilebesiran in eine globale Phase-3-Studie zu kardiovaskulren Endpunkten weiterentwickeln Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das fhrende Unternehmen im Bereich RNAi-Therapeutika, gab heute Plne bekannt, eine Phase-3-Studie zu kardiovaskulren Endpunkten (CVOT) zu initiieren, um das Potenzial von Zilebesiran zur Verringerung des Risikos schwerwiegender kardiovaskulrer Ereignisse zu evaluieren. Diese Entscheidung basiert auf den Ergebnissen des umfassenden KARDIA-Phase-2-Programms, einschlielich der KARDIA-3-Daten, die heute als Late-B
30-Aug-2025 5:34 PM CST - Business Wire Resumen: Alnylam iniciar el ensayo global de fase 3 de Zilebesiran en resultados cardiovasculares Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la principal empresa de terapias basadas en ARN de interferencia (RNAi), anunci hoy que planea iniciar un ensayo de resultados cardiovasculares de fase 3 (CVOT) con el fin de evaluar el potencial de zilebesiran para reducir el riesgo de eventos cardiovasculares adversos mayores. El comunicado en el idioma original es la versin oficial y autorizada del mismo. Esta traduccin es
27-Aug-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentations at Upcoming September Investor Conferences Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025 at 1:45 pm ET in Boston Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025 at 1:05 pm ET in New York City Bernstein Insights: Healthcare Leaders and Disru
5-Jan-2026 8:15 AM CST - Business Wire Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. During the presentation, the Company will unveil its new five-year strategy, which will guide the Companys next phase of gro
4-Nov-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentations at Upcoming November Investor Conferences Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, at 11:30 AM GMT (6:30 AM ET) in London A live audio webcast of each presentation will b
30-Oct-2025 7:00 AM CST - Business Wire Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed recent business highlights. Alnylams impressive third quarter financial results underscore our ability to consistently deliver innovative medicines to patients around the world, said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. While only in our se
16-Oct-2025 7:00 AM CST - Business Wire Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2025 results as well as expectations for the future via conference call on Thursday, October 30, 2025 at 8:30 am ET. A live audio w
31-Aug-2025 2:38 PM CST - Business Wire Alnylam wird Zilebesiran in eine globale Phase-3-Studie zu kardiovaskulren Endpunkten weiterentwickeln Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das fhrende Unternehmen im Bereich RNAi-Therapeutika, gab heute Plne bekannt, eine Phase-3-Studie zu kardiovaskulren Endpunkten (CVOT) zu initiieren, um das Potenzial von Zilebesiran zur Verringerung des Risikos schwerwiegender kardiovaskulrer Ereignisse zu evaluieren. Diese Entscheidung basiert auf den Ergebnissen des umfassenden KARDIA-Phase-2-Programms, einschlielich der KARDIA-3-Daten, die heute als Late-B
30-Aug-2025 5:34 PM CST - Business Wire Resumen: Alnylam iniciar el ensayo global de fase 3 de Zilebesiran en resultados cardiovasculares Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la principal empresa de terapias basadas en ARN de interferencia (RNAi), anunci hoy que planea iniciar un ensayo de resultados cardiovasculares de fase 3 (CVOT) con el fin de evaluar el potencial de zilebesiran para reducir el riesgo de eventos cardiovasculares adversos mayores. El comunicado en el idioma original es la versin oficial y autorizada del mismo. Esta traduccin es
27-Aug-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentations at Upcoming September Investor Conferences Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025 at 1:45 pm ET in Boston Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025 at 1:05 pm ET in New York City Bernstein Insights: Healthcare Leaders and Disru
